Key Stats for Avantor Stock
- Past-Week Performance: -18%
- 52-Week Range: $9 to $18
- Current Price: $9
What Happened to Avantor Stock?
Avantor (AVTR) stock has lost 50% of its value over the past year, falling from above $18 to $9, with the most recent blow coming from a 12.2% premarket drop on February 11 after earnings and an 18% slide the prior week.
Q4 2025 results landed with adjusted EPS in-line at $0.22 and a narrow revenue beat of $1.66 billion against the $1.64 billion estimate, but the stock sold off sharply as 2026 guidance called for another year of organic revenue decline and adjusted EPS of $0.77 to $0.83, down from $0.90 in 2025.
The guidance disappointment reflected persistent volume pressure across laboratory distribution, difficult year-over-year comparisons in Electronic Materials, Serum, and NuSil, plus margin contraction of 100 to 150 basis points driven by revival investment spend, incentive compensation resets, and unfavorable product mix.
Investors are now pricing Avantor as a turnaround story with no clear timeline, as three consecutive years of organic decline, an $785 million impairment charge in 2025, and a net loss of $530 million have stripped the company of the growth premium it once carried.
Emmanuel Ligner, President and Chief Executive Officer, stated on the Q4 2025 earnings call that “2026 will be a year of transition and purposeful investment, and our priority is driving top line growth by competing vigorously in the marketplace and strengthening our company,” framing the VWR brand relaunch and $20 million supply chain investment as the foundation for recovery.
With a consensus hold rating from 15 of 20 analysts and a median price target of $12.05 that already sits 31% above the current $9.21 price, Wall Street is watching for execution rather than upgrading on conviction.
Avantor’s story now hinges entirely on whether the Revival program can stabilize organic growth by year-end 2026, with biopharma production demand remaining healthy but U.S. government and education spending uncertainty, operational bottlenecks in process chemicals, and leverage still at 3.2x creating a narrow path to recovery.
Where is the AVTR Stock Headed?
The double-digit earnings selloff, an 18% slide the prior week, and a current price of $9.21 sitting just 3.5% above its 52-week low of $8.90 tells the full story of how far Wall Street’s confidence in Avantor has eroded, with the stock now trading 49% below its 52-week high of $18.02.
The numbers make the bull case narrow but real: consensus forecasts free cash flow of $500 to $550 million in 2026, EBITDA margins are expected to stabilize around 15%, and the underlying biopharma production business still carries a 26.7% adjusted operating margin in the new Bioscience and Medtech Products segment.
Wall Street’s mean price target has collapsed alongside the stock, falling from $27.20 at the end of 2024 to $10.89 today, yet even that depressed target implies 18.3% upside from the current price, with only 3 buys remaining among 18 analysts versus 14 holds and 1 sell.
The target range stretches from a low of $8.00 to a high of $19.00, a spread that signals analysts are genuinely split on whether Revival stabilizes the business or whether Avantor grinds closer to its 52-week low of $8.90 under continued margin pressure and leverage at 3.2x EBITDA.
Against five consecutive years of revenue and EPS decline, a mid-case valuation model prices AVTR at $11.66 by December 2030, offering a 26.6% total return and a 5.0% annualized IRR, a return profile that barely compensates investors for the execution risk they are absorbing during this transition year.
The core risk is that organic revenue never inflects, with U.S. government and education spending frozen, NuSil and Electronic Materials facing difficult comps, and process chemicals supply chain bottlenecks requiring capital-intensive fixes that compete directly with the company’s stated priority of reducing leverage below 3x.
At $9.21 and hovering near a 52-week low, AVTR is a wait-and-see stock where the upside is real on paper but the fundamental trend demands at least two quarters of improving organic revenue before the market assigns any credibility to the Revival story.
Value Any Stock in Under 60 Seconds (It’s Free)
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
